Macrocycles as factor xia inhibitors
US-2016362414-A1 · Dec 15, 2016 · US
MCL-1 inhibitors
US10703733B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10703733-B2 |
| Application number | US-201916410457-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 13, 2019 |
| Priority date | May 14, 2018 |
| Publication date | Jul 7, 2020 |
| Grant date | Jul 7, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound, or a pharmaceutically acceptable salt thereof, selected from: 2. A compound, or a pharmaceutically acceptable salt thereof, selected from:
Assignees
Inventors
Classifications
- C07D513/08Primary
Bridged systems · CPC title
- A61K31/553Primary
having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine · CPC title
Antineoplastic agents · CPC title
- C07D267/20Primary
[b, f]-condensed · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10703733B2 cover?
- The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
- Who is the assignee on this patent?
- Gilead Sciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D513/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).